Dose dependent effects of O2/O3 therapy on PSA levels of patient with risk of prostate cancer

Background

Men diagnosed with low- or intermediate-risk prostate cancer are sometimes offered "active surveillance" instead of immediate surgery or radiotherapy - a strategy of monitoring the disease closely with regular prostate-specific antigen (PSA) blood tests and imaging, rather than treating it straight away. Some patients on this pathway look for complementary approaches that might help support their PSA trajectory while they watch and wait. This case report examines whether oxygen-ozone (O2/O3) therapy, delivered at different doses over time, had any measurable effect on PSA levels in one such patient.

Study design

This is a single case report describing one 64-year-old man with an intermediate risk of prostate cancer who had chosen active surveillance rather than conventional treatment. Over roughly a year, he received O2/O3 therapy divided into four sequential phases, with the ozone dose and delivery method adjusted between phases. Treatment methods included major autohemotherapy (where a sample of the patient's blood is mixed with an ozone-oxygen gas mixture and reinfused), ozonated saline solution given intravenously, and ozone sauna sessions. PSA blood tests were used as the marker to track change at the end of each phase.

Findings

The patient's PSA level rose from 9.7 ng/mL to 14.7 ng/mL during the second and third phases of treatment, then fell to 11.7 ng/mL by the end of the fourth phase, when the ozone dose and frequency were adjusted. In other words, PSA did not fall steadily throughout treatment - it rose before falling, and the final reading remained above where it started.

What the authors concluded

The author suggested that O2/O3 therapy, when used at the "correct" concentrations and frequency, may have potential as a complementary option for men managing prostate cancer risk through active surveillance. The paper frames this as an early, dose-dependent observation rather than a proven effect, and calls for further study.

Limitations of this study

This is a single case report involving one patient, with no control group and no comparison to similar patients on active surveillance who did not receive ozone therapy. PSA levels are affected by many factors besides ozone exposure, including inflammation, prostate size, and normal biological variation, so a rise-then-fall pattern in one person cannot be attributed to the ozone doses alone. The study does not report imaging or biopsy outcomes alongside the PSA changes, and findings from a single patient cannot be generalised to others. This study concerns PSA levels in a man at risk of prostate cancer. It does not establish ozone as a treatment or cure for cancer itself. Ozone therapy is a complementary approach and should always be discussed with your oncology team.